الفهرس 
INTRODUCTIONOnly 14 pages are availabe for public view
 |  | from | 47 |  |  |
| | | from | 47 | | |
Abstract
Myasthenia gravis (MG) is a disease of neuromuscular junction mostly caused by antibodies against post-synaptic muscle membrane components.
It usually presents by muscle weakness with fluctuating severity during the same day. Incidence in pediatrics ranges from 1.0 to 5 per million per year in Europe, Africa and North America
Myasthenia gravis in children is either congenital or acquired. Children with MG present mainly by ocular symptoms, mainly ptosis. Ocular manifestation may be the only symptom in 20% of cases.
Muscle weakness may be generalized affecting limb muscles and respiratory muscles causing respiratory failure in severe cases.
Diagnosis of MG is mainly based on the clinical presentation. That’s supported by further confirmatory tests including pharmacologic, serologic and electrophysiologic tests.
Treatment options for adults with MG can be adapted for children with special consideration of doses and side effects of drugs. This includes symptomatic treatment and immunosuppressive agents.
This study aims at providing a profile of childhood myasthenia gravis in children attending Alexandria University Children’s Hospital. A descriptive approach was selected to fulfill the study objectives.
Our study revealed that there is fifteen cases of childhood myasthenia gravis following at pediatric neurology clinic in Alexandria University Children’s Hospital during the studied period males represented of 26.7% (4patients). Females represented 73.3% (11 patients), with male to female ratio 1:2.75. The mean duration of follow up in our study was 2.87 years.